#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Henoch-Schonlein purpura Hypereosinophilic syndrome Macular telangiectasia Epidermolysis bullosa Idiopathic pulmonary fibrosis Necrotising myositis Anal cancer recurrent Malignant peritoneal neoplasm Tourette's disorder Neuroendocrine carcinoma Chronic kidney disease Adenocarcinoma gastric Antisynthetase syndrome Canavan disease Mastocytosis More trials…

    Learn about Rare Diseases

    Hepatoblastoma – Treatment Mucopolysaccharidosis – Basic Information Familial amyotrophic lateral sclerosis Progressive supranuclear palsy – Diagnostics Pemphigus – Basic Information Indolent systemic mastocytosis – Diagnostics Anaplastic thyroid cancer – Diagnostics Synovial sarcoma metastatic – Basic Information Methylmalonic acidaemia – Treatment Prader-Willi syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Minzasolmin Talazoparib Danicamtiv Elivaldogene Autotemcel Defactinib Crn04894 Allopurinol Sodium Pentetic Acid CICLOPIROX Rozanolixizumab Histamine Hydrochloride Prednisone Gad20-209-Fsp-A2 Benralizumab GSKVX000000030918 Clenbuterol Hydrochloride Levosimendan ADMILPARANT Urokinase Betamethasone More therapies…

    Learn about Your Condition

    Oesophagectomy Postoperative wound infection Richter's syndrome Childhood asthma Ventricular fibrillation Endocarditis bacterial Iron deficiency anaemia Small intestine leiomyosarcoma Procedural hypotension Diabetic foot Transplant rejection Medulloblastoma recurrent Skin papilloma Wiskott-Aldrich syndrome Partial lipodystrophy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Central nervous system lymphoma

  • Study of Lisocabtagene Maraleucel as First Treatment for Adults with Primary Central Nervous System Lymphoma Who Cannot Have a Stem Cell Transplant

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Central nervous system lymphoma
    Investigated Drugs:
    • Calcium Folinate
    • Fludarabine
    • Lisocabtagene Maraleucel
    France Germany

  • Study of Epcoritamab, Lenalidomide, and Rituximab for Patients with Relapsed and Refractory Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma
    • Central nervous system lymphoma
    Investigated Drugs:
    • Epcoritamab
    • Lenalidomide
    • Rituximab
    France

  • Study on Golcadomide and Valemetostat Tosylate for Patients with Relapsed or Refractory Non-Hodgkin Lymphomas

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Valemetostat Tosilate
    • Golcadomide
    • Rituximab
    Denmark France Italy Spain

  • Study on the Safety of CA-4948 and Ibrutinib for Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Emavusertib
    • Ibrutinib
    Czechia France Italy Poland Spain

  • Study of Tirabrutinib, Rituximab, and Temozolomide in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Temozolomide
    • Rituximab
    Austria Belgium Czechia France Germany Italy +2

  • Study on the Effectiveness of Etoposide Phosphate, Carboplatin, Methotrexate, Rituximab, and Cyclophosphamide in Patients with Primary Central Nervous System Lymphoma

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Central nervous system lymphoma
    Investigated Drugs:
    • Etoposide Phosphate
    • Methotrexate
    • Carboplatin
    Finland
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!